Located in South Florida, Kimera® Labs was founded in 2012 and manufactures state-of-the-art exosomes and other biologic products for the clinical and research community. The company operates the only FDA audited exosome production process which is manufactured in a 27,000 square foot GMP laboratory in Miramar, Florida. To date, the company’s first publicly available isolated exosome product, XoGlo®, has treated over 45,000 patients for a variety of investigational indications. Exosomes have been referenced in numerous peer-reviewed scientific publications while exhibiting anti-inflammatory and growth instantiating properties. The success of these therapies has led to a current FDA IND application for post COVID-19 symptom treatment. Since 2012, Kimera® has demonstrated an unmatched approach to quality driven, scalable, GMP nano-particle production.

The fundamental purpose of Kimera Labs is the advancement of the exosomes industry through research and development, clinical investigation and support of health care providers.

As we make progress with our own developments in exosome technology, Kimera Labs continues to collect scientific evidence about the nature of exosomes and their unique biologic properties. Kimera Labs will continue to support clinical studies on MSC exosomes and will complete investigational trials for exosome-based pharmaceutical products.

Indication-specific, engineered exosomes and optimized delivery systems for MSC exosomes are likely to play a significant role in the future of healthcare, and Kimera Labs is at the forefront of exosome technology development for regenerative medicine applications, all in support of health care providers and ultimately, their patients.